WO2009120700A3 - Inhibition de dcps - Google Patents

Inhibition de dcps Download PDF

Info

Publication number
WO2009120700A3
WO2009120700A3 PCT/US2009/038108 US2009038108W WO2009120700A3 WO 2009120700 A3 WO2009120700 A3 WO 2009120700A3 US 2009038108 W US2009038108 W US 2009038108W WO 2009120700 A3 WO2009120700 A3 WO 2009120700A3
Authority
WO
WIPO (PCT)
Prior art keywords
dcps
inhibition
smn
subject
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/038108
Other languages
English (en)
Other versions
WO2009120700A2 (fr
Inventor
Jill Jarecki
Jasbir Singh
Mark Gurney
Brian A. Pollok
Gregory Michaud
Shin-Wu Liu
Megerditch Kiledjian
Matthew Butchbach
Arthur Burghes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Ohio State University
Families of Spinal Muscular Atrophy
Original Assignee
Rutgers State University of New Jersey
Ohio State University
Families of Spinal Muscular Atrophy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey, Ohio State University, Families of Spinal Muscular Atrophy filed Critical Rutgers State University of New Jersey
Publication of WO2009120700A2 publication Critical patent/WO2009120700A2/fr
Publication of WO2009120700A3 publication Critical patent/WO2009120700A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des procédés et des compositions (par exemple, des composés et des compositions pharmaceutiques de ceux-ci) utiles pour augmenter l'expression de SMN dans une cellule (par exemple, in vitro ou in vivo). Étant donné qu'une déficience en SMN peut conduire au développement d'une condition de SMA chez un sujet, les procédés et les compositions décrits ici peuvent également être utilisés, par exemple, pour traiter ou prévenir un état de SMA chez un sujet.
PCT/US2009/038108 2008-03-26 2009-03-24 Inhibition de dcps Ceased WO2009120700A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7204008P 2008-03-26 2008-03-26
US61/072,040 2008-03-26

Publications (2)

Publication Number Publication Date
WO2009120700A2 WO2009120700A2 (fr) 2009-10-01
WO2009120700A3 true WO2009120700A3 (fr) 2009-12-30

Family

ID=41114646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/038108 Ceased WO2009120700A2 (fr) 2008-03-26 2009-03-24 Inhibition de dcps

Country Status (1)

Country Link
WO (1) WO2009120700A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2699827T3 (es) 2009-06-17 2019-02-13 Biogen Ma Inc Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
US20130096160A1 (en) * 2010-04-14 2013-04-18 Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
WO2014110291A1 (fr) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions et procédés pour la modulation de l'épissage de smn2 chez un sujet
EP3797780B1 (fr) 2014-04-17 2022-09-14 Biogen MA Inc. Compositions et procédés de modulation de l'épissage du smn2 chez un sujet
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
EP3377073A4 (fr) 2015-11-16 2019-06-26 Ohio State Innovation Foundation Méthodes et compositions pour traiter des troubles et des maladies à l'aide de la protéine de survie des motoneurones (smn)
US11198867B2 (en) 2016-06-16 2021-12-14 Ionis Pharmaceuticals, Inc. Combinations for the modulation of SMN expression
CN120505310A (zh) 2020-02-28 2025-08-19 Ionis制药公司 用于调节smn2的化合物和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288314A1 (en) * 2004-06-08 2005-12-29 Decode Chemistry, Inc. 2,4-diaminoquinazolines for spinal muscular atrophy
US20090042900A1 (en) * 2006-08-01 2009-02-12 Decode Chemistry, Inc. 2,4-diaminoquinazolines for spinal muscular atrophy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288314A1 (en) * 2004-06-08 2005-12-29 Decode Chemistry, Inc. 2,4-diaminoquinazolines for spinal muscular atrophy
US20090042900A1 (en) * 2006-08-01 2009-02-12 Decode Chemistry, Inc. 2,4-diaminoquinazolines for spinal muscular atrophy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAVIES ET AL.: "Spinal muscular atrophies-distinctions and therapeutic progress.", DRUGS OF THE FUTURE, vol. 31, no. 4, 2006, pages 365 - 371 *
LIU ET AL.: "The scavenger mRNA decapping enzyme DcpS is a member of the HIT family of pyrophosphatases.", EMBO J., vol. 21, no. 17, 2002, pages 4699 - 4708 *
THURMOND ET AL.: "Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.", J MED CHEM., vol. 51, no. 3, 14 February 2008 (2008-02-14), pages 449 - 469 *

Also Published As

Publication number Publication date
WO2009120700A2 (fr) 2009-10-01

Similar Documents

Publication Publication Date Title
WO2009120700A3 (fr) Inhibition de dcps
WO2010062863A3 (fr) Compositions contenant des satiogènes et leurs procédés d'utilisation
WO2010017562A3 (fr) Cellules souches pluripotentes induites
EP2330894B8 (fr) Compositions comprenant des dérivés d acide 6-aminohexanoïque utilisées comme inhibiteurs de hdac
WO2010065709A3 (fr) Dérivés d'acide hydroxamique, préparation et utilisations thérapeutiques de ceux-ci
MY158504A (en) Fatty acid niacin conjugates and their uses
ZA201008398B (en) An electrochemically active composition,methods of making,and uses thereof
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
WO2009134389A9 (fr) Anticorps anti-cd137 en tant qu'agent dans le traitement d'états inflammatoires
MY166789A (en) Arginine salts and their uses for the treatment of illnesses in the oral cavity
WO2008132229A3 (fr) Solutions et compositions hautement concentrées en insuline
WO2010002956A3 (fr) Dérivés hétérocycliques en tant que modulateurs des canaux ioniques
WO2009151907A3 (fr) Compositions et procédés permettant d'utiliser des cellules pour traiter le tissu cardiaque
WO2010062911A3 (fr) Compositions et procédés de système de culture cellulaire in vitro fonctionnellement amélioré
WO2010132882A8 (fr) Compositions sublinguales de dexmédétomidine et leurs procédés d'utilisation
WO2010048358A3 (fr) Inhibiteurs à base d'éthoxyphénylméthyle de sglt2
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
WO2008016730A3 (fr) Compositions et procédés pour réduire la graisse cellulaire
WO2009111586A3 (fr) Évolution autonome in vitro
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
IL213177A0 (en) Crystal forms, methods of preparation, pharmaceutical compositions and uses of nicousamide
WO2010057647A3 (fr) Procédés et compositions pour le diagnostic et le traitement du diabète
PT2222839E (pt) Métodos e composições para modular a diferenciação de células pluripotentes
HK1209650A1 (en) Method and composition for metabolic regulation
WO2011156820A9 (fr) Compositions, méthodes et utilisations pour le traitement du diabète insulino-dépendant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09726238

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09726238

Country of ref document: EP

Kind code of ref document: A2